ArticleLeukemia & lymphoma2021
Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?
Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- EASIX score is predictive of early fatal complications in newly diagnosed acute myeloid leukemia.Annals of hematology · 2026Article
- The Diagnostic Evolution of Haematological Neoplasms: A Narrative Review of the Road to Two Genetically Focused Classification Systems Through a Resource-Limited Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Risk factors and management strategies in acute promyelocytic leukemia: a real-world single-center retrospective study.Frontiers in medicine · 2026Article
- Association between leukemic immunophenotype and overall survival in patients with acute promyelocytic leukemia: a retrospective cohort study.Frontiers in cell and developmental biology · 2026Article
- Predictors of Early Death in Acute Promyelocytic Leukemia.Medical sciences (Basel, Switzerland) · 2025Review
- Clinical characteristics and outcome of pediatric patients with high-risk acute promyelocytic leukemia, with special focus on risk factors of early death.Annals of hematology · 2025Article
- An unusual and incidental diagnosis of acute promyelocytic leukaemia through eye casualty.Journal of surgical case reports · 2025Article
- Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them.Cancers · 2024Review
- Causes and risk factors for early death in adult patients with acute promyelocytic leukemia: a real-life experience.Hematology, transfusion and cell therapy · 2024Article
- The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients.Annals of hematology · 2024Article
- Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis.Annals of hematology · 2023Article
- Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.BMC cancer · 2023Article
- Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States.Blood advances · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acute promyelocytic leukemia (APL) boasts overall survival (OS) of >90% at 3 years and early mortality of <5% in recent clinical trials. Using a large National Cancer Database, we performed analysis of 7190 adults with APL to determine whether one-month mortality and OS of patients with APL treated in real-world practices mirror outcomes noted in clinical trials. Only 64% of total patients received multi-agent therapy; 32% received either single-agent therapy or no therapy at all. One-month mortality was 6% for patients ≤18 years, 6% for 19-40 years, 10% for 41-60 years, and 21% for >60 years. OS at 1- and 3-year were 81% and 75%, respectively. In a multivariate analysis, age ≤ 40 years, treatment at academic center, use of multi-agent therapy, and diagnosis after 2009 conferred better OS. In this largest database study in APL till date, we demonstrated an overall improvement in OS over time but challenges still exist in translating successes of clinical trials to real-world practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.